New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150 mg/ml - solution for injection - 75 mg/0.5ml - active: omalizumab 150 mg/ml excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate polysorbate 20 water for injection - xolair (omalizumab) is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige greater than or equal to 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 20 mg/2ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 80 mg/8ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - isradipine 2.5mg;  ;   - modified release capsule - 2.5 mg - active: isradipine 2.5mg     excipient: cetyl palmitate colloidal silicon dioxide gelatin hypromellose ink iron oxide yellow magnesium stearate microcrystalline cellulose titanium dioxide - treatment of hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - isradipine 5mg;  ;   - modified release capsule - 5 mg - active: isradipine 5mg     excipient: cetyl palmitate colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - treatment of hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - baclofen 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: baclofen 0.05 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - baclofen 2 mg/ml - solution for injection - 10 mg/5ml - active: baclofen 2 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - metoprolol tartrate 5mg;   - solution for injection - 5 mg/5ml - active: metoprolol tartrate 5mg   excipient: nitrogen sodium chloride water for injection - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ranibizumab 10 mg/ml - solution for injection - 10 mg/ml - active: ranibizumab 10 mg/ml excipient: histidine histidine hydrochloride polysorbate 20 trehalose dihydrate water for injection - lucentis® is indicated for the treatment of neovascular (wet) age-related macular degeneration (amd).

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - metoprolol tartrate 200mg - modified release tablet - 200 mg - active: metoprolol tartrate 200mg excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide ethanol as ethanol with 5% isopropyl alcohol -not in final product glyceryl palmito-stearate hypromellose   iron oxide yellow magnesium stearate methacrylic acid copolymer as eudragit e 30 d microcrystalline cellulose polysorbate 80 purified talc purified water titanium dioxide - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.